65G Stock Overview A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
NextCell Pharma AB Competitors Price History & Performance
Summary of share price highs, lows and changes for NextCell Pharma Historical stock prices Current Share Price SEK 0.21 52 Week High SEK 0.29 52 Week Low SEK 0.063 Beta 0.52 1 Month Change 15.70% 3 Month Change 90.91% 1 Year Change 11.11% 3 Year Change -71.47% 5 Year Change n/a Change since IPO -89.46%
Recent News & Updates
NextCell Pharma AB Reports New Results from the ProTrans-Repeat Study Dec 18
Full year 2024 earnings released: kr1.22 loss per share (vs kr1.16 loss in FY 2023) Oct 25 NextCell Pharma AB to Report Q1, 2025 Results on Jan 30, 2025
NextCell Pharma AB Announces Drug Candidate ProTrans Highlighting in Dagens Medicin's Latest Edition Featuring Ongoing Research Advances in the Treatment of Type 1 Diabetes Oct 04
NextCell Pharma AB Announces the First Children Have Been Treated in the Young Age Group of the ProTrans-Young Study Oct 01
NextCell Pharma AB Presents New Long-Term Clinical Data at the International Society for Cell and Gene Therapy 2024 Regional Meeting Sep 05 See more updates
NextCell Pharma AB Reports New Results from the ProTrans-Repeat Study Dec 18
Full year 2024 earnings released: kr1.22 loss per share (vs kr1.16 loss in FY 2023) Oct 25 NextCell Pharma AB to Report Q1, 2025 Results on Jan 30, 2025
NextCell Pharma AB Announces Drug Candidate ProTrans Highlighting in Dagens Medicin's Latest Edition Featuring Ongoing Research Advances in the Treatment of Type 1 Diabetes Oct 04
NextCell Pharma AB Announces the First Children Have Been Treated in the Young Age Group of the ProTrans-Young Study Oct 01
NextCell Pharma AB Presents New Long-Term Clinical Data at the International Society for Cell and Gene Therapy 2024 Regional Meeting Sep 05
Third quarter 2024 earnings released Jul 26
New major risk - Shareholder dilution Jul 01
Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study Jun 13
Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board May 28
Second quarter 2024 earnings released Apr 26
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue Apr 24
NextCell Pharma AB, Annual General Meeting, Nov 28, 2024 Apr 20 Anders Essen-Möller Resigns as Chairman of NextCell Pharma AB Apr 19
The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study Mar 29
First quarter 2024 earnings released Jan 26
Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans Jan 24
Full year 2023 earnings released Oct 29 NextCell Pharma AB to Report Fiscal Year 2024 Results on Oct 24, 2024
Third quarter 2023 earnings released Jul 28
NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans Jul 06
Second quarter 2023 earnings released Apr 30
First quarter 2023 earnings released Jan 27 NextCell Pharma AB to Report Fiscal Year 2023 Final Results on Nov 09, 2023
NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study Dec 22
Less than half of directors are independent Nov 16
Full year 2022 earnings released Nov 06
Nextcell Pharma AB Announces Trial with Protrans Gets Green Light for Phase Ii Part Oct 29
Nextcell Cell Therapy Shows Long-Term Effect in Two Independent Diabetes Studies "ProTrans-Repeat" and "ProTrans-Obs"- Live Presentation Oct 25
Nextcell Pharma AB Announces Protrans Cell Therapy Provides Long-Term Effect in Type-1 Diabetes with A Single Treatment Oct 21
NextCell Pharma AB Announces Type-1 Diabetes Patients Receiving Two Treatments with A High Dose of Protrans Cell Therapy Oct 19
NextCell Pharma AB Announces ProTrans Cell Therapy to Be Granted Patent Protection Beyond Europe Aug 26
Third quarter 2022 earnings released Jul 31
NextCell Pharma AB Announces Patients in the First Part of Pediatric Diabetes Trial with Nextcell's Protrans Treated Jun 09
The European Patent Office intends to grant a Patent to NextCell Pharma AB for Selection Algorithm May 31
Second quarter 2022 earnings released Apr 29
Less than half of directors are independent Apr 27
NextCell Pharma AB Announces First Age Group Treated in Paediatric Diabetes Study with Protrans Apr 08
NextCell Pharma AB Announces Clinical Trial ProTrans19+CA Expanded to Include an Additional Site: The Jewish General Hospital In Montreal, Canada Feb 24
NextCell Pharma AB Announces Pediatric Diabetes Study with ProTrans in Progress Feb 22
First quarter 2022 earnings: Revenues in line with analyst expectations Jan 29 NextCell Pharma AB to Report Fiscal Year 2022 Final Results on Nov 03, 2022
Full year 2021 earnings released: kr0.71 loss per share (vs kr0.89 loss in FY 2020) Oct 31
Third quarter 2021 earnings released Aug 01
NextCell Pharma AB Announces COVID-19 Patient Treated with ProTrans Jun 11
NextCell Presents Their Latest Phase II Clinical Data at ISCT 2021 May 29
NextCell Pharma AB Announces That Both the Canadian and Swedish Covid-19 Studies Have Been Initiated and Are Now Ready to Include Patients with Severe Pneumonia Triggered by Sars-Cov-2 Infection May 27
Nextcelpharmama AB Recruitments Start for the Protrans Study for Treatment of Covid-19 May 21
Second quarter 2021 earnings released May 01
New 90-day low: €1.50 Feb 20
NextCell Pharma AB Announces Canadian Trial for ProTrans in COVID-19 Feb 04
First quarter 2021 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2020) Jan 30 NextCell Pharma AB, Annual General Meeting, Nov 24, 2021
Nextcell Pharma AB Announces Observational Study, Protrans-Obs, receives Approval by the Swedish Ethical Review Board Dec 16
NextCell Pharma AB Supports ProTrans Study for Children and Adolescents Nov 18
Nextcell Starts Eurostars Funded Project Bioscale Nov 11 Shareholder Returns 65G DE Biotechs DE Market 7D -1.9% 1.0% 1.9% 1Y 11.1% -4.3% 15.1%
See full shareholder returns
Return vs Market: 65G underperformed the German Market which returned 15.1% over the past year.
Price Volatility Is 65G's price volatile compared to industry and market? 65G volatility 65G Average Weekly Movement 16.2% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 65G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 65G's weekly volatility has decreased from 46% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
Show more NextCell Pharma AB Fundamentals Summary How do NextCell Pharma's earnings and revenue compare to its market cap? 65G fundamental statistics Market cap €18.57m Earnings (TTM ) -€3.50m Revenue (TTM ) €821.99k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 65G income statement (TTM ) Revenue SEK 9.45m Cost of Revenue SEK 15.06m Gross Profit -SEK 5.61m Other Expenses SEK 34.59m Earnings -SEK 40.21m
Last Reported Earnings
Nov 30, 2024
Next Earnings Date
Apr 25, 2025
Earnings per share (EPS) -0.55 Gross Margin -59.42% Net Profit Margin -425.55% Debt/Equity Ratio 0%
How did 65G perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/02 21:09 End of Day Share Price 2025/01/31 00:00 Earnings 2024/11/30 Annual Earnings 2024/08/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NextCell Pharma AB is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
